skip main site navigation go to current site section navigation


Lung Therapeutics(LTI) leverages NIH validated and funded programs to develop first in class therapies for niche indications in lung injury and disease. LTI was funded in part by the UT Horizon Fund (as well as other sources), and all development work was paid for by an NIH translational grant. The company takes advantage of more than 25 years of research in lung disease and it pursues indications for which there is no effective therapeutic option. Its first project, LTI-01, has received over $12M in funding, and addresses an unmet need in a billion dollar global market.